<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48743">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02471664</url>
  </required_header>
  <id_info>
    <org_study_id>TPMMLC</org_study_id>
    <nct_id>NCT02471664</nct_id>
  </id_info>
  <brief_title>Mitral Loop Cerclage(MLC) for Reducing Functional Mitral Regurgitation</brief_title>
  <official_title>The Study on Safety and Feasibility of Mitral Loop Cerclage(MLC) Annuloplasty Procedure With Investigational Medical Device (MLC-B-45-75-R and Other 11 Models) : Single-centre, Open Label, Single Arm, Feasibility Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tau Pnu Medical Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tau Pnu Medical Co.,Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate safety and feasibility of Mitral Loop Cerclage(MLC) Annuloplasty with CSTV for
      repair of functional mitral regurgitation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this prospective, single-center, open label, feasibility test is to assess
      the safety and efficacy of Mitral Loop Cerclage Annuloplasty with CSTV protective device in
      treating functional mitral regurgitation (FMR) associated with heart failure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of mitral regurgitation severity by regurgitant volume (RV) and effective regurgitant orifice (ERO)</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in mitral annulus geometry (septal lateral dimension)</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of adverse events as a measure of safety</measure>
    <time_frame>1 month</time_frame>
    <description>Rate of composite endpoint of MACE (Major Adverse Cardiac Event)
* Death, myocardial infarction, cardiac tamponade, device related cardiac surgery, stroke</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of mitral regurgitation severity by regurgitant volume (RV) and effective regurgitant orifice (ERO)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mitral annulus geometry (septal lateral dimension)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mitral valve hemodynamics</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricle volumes</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in subjects' symptoms referred to NYHA (New York Heart Association) Classification System</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success rate of the implantation and technical feasibility</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse events as a measure of safety</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of composite endpoint of MACE (Major Adverse Cardiac Event)
* Death, myocardial infarction, cardiac tamponade, device related cardiac surgery, stroke</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Functional Mitral Regurgitation</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Single</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Device: Mitral Loop Cerclage Annuloplasty with CSTV Protective Device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mitral Loop Cerclage Annuloplasty</intervention_name>
    <arm_group_label>Single</arm_group_label>
    <other_name>MLC series (MLC-B-45-75-R and other 11 models)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  NYHA(New York Heart Association) Class III - IV, and symptomatic severe functional MR
             by 2014 ACC/AHA guideline in spite of optimal medical treatment.

        (For optimal medical treatments, ①ACE inhibitor or angiotensin receptor blocker ②β-blocker
        ③ aldosterone antagonists should be given for at least 3 months unless the subject has
        contraindication for each drug)

        Exclusion Criteria:

          -  Primary Mitral Regurgitation

          -  LV ejection fraction lower than 25%

          -  Creatinine ≥2.0 mg/dL

          -  Anomaly of Coronary Sinus

          -  Pre-existing devices in coronary sinus such as Implantable Cardioverter Defibrillator
             and Pacemaker

          -  2:1 Atriventricular AV block or higher AV block and ventricular tachycardia

          -  Subjects with functional MR who need CABG or AVR performed

          -  Subjects who have functional MR caused by aortic valve disease

          -  Subjects who have uncontrollable hyperthyroidism

          -  Subjects who have severe TR due to primary valve leaflet disease

          -  Subjects who cannot be screened by cardiac CT

          -  Subjects who have possibility of coronary artery pinching even with Mitral Loop
             Cerclage system judged by cardiac CT

          -  Subjects who are unable to take anti-platelet agents

          -  Subjects who are participated in other clinical trials within 1 month of enrollment

          -  Subjects who have coagulation disorders

          -  Subjects who have thrombosis and embolism

          -  Subjects who are pregnant, or lactating, or plan pregnancy during the clinical trials

          -  Subjects who are deemed not to be eligible in this study by physician's discretion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>June-Hong Kim, MD, Ph D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pusan National University Yangsan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>June-Hong Kim, MD, Ph D</last_name>
    <phone>82-55-360-2355</phone>
    <email>junehongk@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Minku Chon, MD, PhD</last_name>
    <phone>82-55-360-1458</phone>
    <email>chonmingu@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Institues of Health</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Lederman, M.D.</last_name>
      <phone>301-402-6769</phone>
      <email>lederman@nih.gov</email>
    </contact>
    <investigator>
      <last_name>Robert Lederman, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Yangsan</city>
        <state>Gyeongsangnamdo</state>
        <zip>626-770</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>June-Hong Kim, MD, Ph D</last_name>
      <phone>82-55-360-2355</phone>
      <email>junehongk@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Minku Chon, MD, PhD</last_name>
      <phone>82-55-360-1458</phone>
      <email>chonmingu@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>June-Hong Kim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Minku Chon, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yonghyun Park, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kiwon Hwang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sanghyun Lee, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeongsu Kim, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Suyong Lee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jongmin Hwang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hyunggon Je, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kiseok Choo, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sichan Sung, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://content.onlinejacc.org/article.aspx?articleid=1139949</url>
    <description>Mitral cerclage annuloplasty, a novel transcatheter treatment for secondary mitral valve regurgitation: Initial results in swine</description>
  </link>
  <results_reference>
    <citation>Kim JH, Kocaturk O, Ozturk C, Faranesh AZ, Sonmez M, Sampath S, Saikus CE, Kim AH, Raman VK, Derbyshire JA, Schenke WH, Wright VJ, Berry C, McVeigh ER, Lederman RJ. Mitral cerclage annuloplasty, a novel transcatheter treatment for secondary mitral valve regurgitation: initial results in swine. J Am Coll Cardiol. 2009 Aug 11;54(7):638-51. doi: 10.1016/j.jacc.2009.03.071.</citation>
    <PMID>19660696</PMID>
  </results_reference>
  <verification_date>June 2015</verification_date>
  <lastchanged_date>June 16, 2015</lastchanged_date>
  <firstreceived_date>June 5, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pusan National University Yangsan Hospital</investigator_affiliation>
    <investigator_full_name>June-Hong Kim, MD, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Percutaneous mitral valve repair</keyword>
  <keyword>Coronary sinus annuloplasty</keyword>
  <keyword>Mitral loop cerclage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
